-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Kymera Therapeutics, Raises Price Target to $118

Benzinga·12/09/2025 13:10:22
語音播報
Leerink Partners analyst Faisal Khurshid maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $70 to $118.